Relmada reported 95% of patients had a complete response at some point, and its cash is expected to fund operations through 2029. FDA-aligned trial plans support a positive outlook, though manufacturing scale-up remains unfinished.
The study results and FDA-aligned trial plans give Relmada a promising path toward larger trials. Its cash is expected to fund operations through 2029, but manufacturing scale-up is unfinished and remains the main risk.
Follow Relmada Therapeutics (RLMD) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for RLMD